Drugstore giant CVS says it fills one of every eight retail prescriptions in the U.S. And Edward Kelly, an analyst at Credit Suisse, says the chain is filling its own prescription for success by making smart acquisitions, generating solid sales growth and bolstering its competitive advantages. The investment firm added the stock to its "focus list" on Wednesday.
CVS, which generates 70% of sales from prescription drugs, should benefit enormously from an aging population and increasing use of pharmaceuticals. As the largest drugstore chain in the country by store count (more than 5,400 at last word), the Woonsocket, R.I., company is in a strong competitive position. Its sheer size and economies of scale should enable CVS to make life difficult for smaller rivals.
CVS has been expanding through acquisitions. The Eckerd stores it acquired in 2004 represent a significant -- and underappreciated -- opportunity to boost earnings, in Kelly's view. CVS agreed earlier this year to purchase about 700 Sav-on and Osco stores from Albertsons, boosting its presence in southern California. Both deals, Kelly says, contribute to a robust earnings outlook.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
In addition to operating the stores, CVS boasts a large pharmacy benefit management business. Businesses enlist PharmaCare to help provide drug coverage to insurance-plan participants. This subsidiary won a contract this week to provide mail-order, specialty-pharmacy and other services to certain employees of automaker DaimlerChrysler. Kelly says winning the contract is a defining moment for CVS because it bestows credibility on the benefit management business and sets the stage for additional wins.
The stock (symbol CVS) gained 4% on Wednesday. At $30, it trades at 19 times analysts' average earnings estimates for 2006 of $1.57 per share, according to Thomson First Call. That's an attractive price according to Kelly's analysis. He thinks the shares can rise to $35 over the next 12 months.
--Lisa Dixon
-
Donating Complex Assets Doesn't Have to Be ComplicatedIf you're looking to donate less-conventional assets but don't know where to start, this charity executive has answers, such as considering a donor-advised fund (DAF) for its tax benefits and ease of use.
-
Travel trends you can expect this summerThe Kiplinger Letter Domestic trips will trump foreign travel amid economic uncertainties, though some costs are down.
-
My Three-Day Rule for Investing: And If it Applies NowStock Market I've seen a lot in my career. Here's what I see now in the stock market.
-
Is It Time to Invest in Europe?Stock Market Europe is being shaken out of its lethargy, militarily and otherwise, by Donald Trump's changes in U.S. policy. Should investors start buying?
-
The Best Health Care Stocks to BuyThe best health care stocks offer investors a defensive hedge in an uncertain market. Here's how to find them.
-
AI vs the Stock Market: How Did Value Stocks, Gold and PayPal Perform in April?AI is a new tool for investors to use for data analysis, but can it beat the stock market? Here's how a chatbot's stock picks fared in April.
-
Stock Market Today: Tariff Talks Drive Another Up-and-Down DayTrade war negotiations are happening, but the "fear gauge" is gyrating, and investors, traders and speculators are still searching for signs of a bottom.
-
Fed Leaves Rates Unchanged: What the Experts Are SayingFederal Reserve As widely expected, the Federal Open Market Committee took a 'wait-and-see' approach toward borrowing costs.
-
How to Hedge Against Trump's TariffsDonald Trump is taking action on tariffs and this could have a big impact on public companies. Here's how investors can prepare.
-
Fed Sees Fewer Rate Cuts in 2025: What the Experts Are Saying
Federal Reserve The Federal Reserve cut interest rates as expected, but the future path of borrowing costs became more opaque.
